Exothera to support process development of Turkish company’s COVID-19 vaccine

By Jane Byrne contact

- Last updated on GMT

© GettyImages/Morsa Images
© GettyImages/Morsa Images

Related tags: drug product manufacturing, COVID-19, Vaccine, Clinical trials

Turkey based Vaccizone has chosen Belgian CDMO, Exothera, to fast-track process development of its COVID-19 vaccine for European clinical trials.

The project will cover proof-of-concept at small scale to drug substance and drug product manufacturing, including DSP process development, analytical toolkit assays set-up, quality control validation and CMC support, said the parties.

It will leverage Exothera’s services such as plasmid supply, full upstream and downstream process development, and manufacturing.

Vaccizone has developed and patented a method for delivering antigens and bioactive compounds to increase the stability and shelf life of complex biotherapeutics, like vaccines, monoclonal antibodies and cell and gene therapies.

The enhanced antigen/bioactive delivery method is based on Antigen Presenting Cells (APCs).

In its COVID-19 vaccine, ASC protein microparticles carry the tRBD domain of the SARS CoV 2 spike protein, forming a fusion with human ASC protein. The firm said the technology increases both the antigenicity of the COVID-19 antigen and enhances its stability at high temperatures, during freeze-thaw cycles, and in the presence of organic solvents.

Vaccines and immune therapies developed with ASC technology are thermostable and eliminate the need for cold-chain logistics for delivery and storage, according to the company.

Exothera is part of the Univercells Group, and Vaccizone said it is set to benefit from the services of the other companies under that umbrella, namely Quantoom Biosciences, Univercells Technologies, and Unizima:

Univercells will support Vaccizone with grant submissions while Unizima can offer deployment capabilities to set up manufacturing facilities in Turkey. Vaccizone and Quantoom Biosciences are also evaluating whether the ASC protein-based platform can be used for mRNA-based therapeutics formulation to improve thermostability and targeted delivery.

Vaccines for developing markets

In April, Exothera announced it had formed a partnership with ReiThera to develop what they called a large-scale, low cost per dose manufacturing process to deliver novel vaccines to low- and middle-income countries (LMICs).

Their collaborative effort was awarded a €3m (US$3.2m) grant by the Bill & Melinda Gates Foundation, with the idea the tie-up would deliver new low-cost vaccines based on ReiThera’s GRAd technology platform, against COVID-19 and HIV, mostly for LMICs in Africa.

The partners are looking to develop a scale-up manufacturing process for the production of ReiThera’s vaccine candidates based on its GRAd platform, including its COVID-19 vaccine candidate (GRAd-COV2).  

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more